Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement. (January 2018)

• Record Type: Journal Article
• Authors: Massaro, L; Ceccarelli, F; Colasanti, T; Pendolino, M; Perricone, C; Cipriano, E; Natalucci, F; Capalbo, G; Lucchetti, R; Pecani, A; Vomero, M; Mancini, R; Spinelli, F R; Alessandri, C; Valesini, G; Conti, F
• Is Part Of: Lupus. Volume 27:Number 1(2018)
• Page Start: 105
• Page End: 111
• Publication Date: 2018-01
• Subjects: Systemic lupus erythematosus -- joint involvement -- anti-CarP; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203317713141
• Languages: English
• ISSNs: 0961-2033

Abstract

Objective: Several studies have evaluated the prevalence of rheumatoid factor (RF) and anti-citrullinated proteins antibodies (ACPA) in systemic lupus erythematosus (SLE) patients but no data are available on the anti-carbamylated proteins (anti-CarP), a new biomarker for rheumatoid arthritis (RA). We evaluated the anti-CarP prevalence in SLE patients with joint involvement and the associations with different phenotypes. Methods: Seventy-eight SLE patients with joint involvement were enrolled (F/M 73/5; mean ± SD age 47.6 ± 11.2 years; mean ± SD disease duration 214.3 ± 115.6 months). As control groups, we evaluated SLE patients without joint manifestations ( N = 15), RA ( N = 78) and healthy individuals (HS, N = 98). Anti-CarP were assessed by home-made ELISA in all patients and controls, RF and ACPA in SLE patients with joint involvement (commercial ELISA kit). Results: The prevalence of anti-CarP in SLE patients with joint involvement was similar to RA ( p = NS) and significantly higher compared with SLE without joint involvement and HS ( p < 0.0001, p < 0.0001, respectively). Four patients were positive for all three antibodies: seventy-five percent of these showed Jaccoud arthropathy. Fourty-five percent of ACPA-ve/RF-ve patients were anti-CarP + ve. Conclusions: The evaluation of anti-CarP in SLE joint involvement demonstrated a prevalence of almost 50%, similar to RA and significantly higher than SLE without joint involvement and HS.